drugset / Trial / NCT00421811

A Study of ADH-1 in Combination With Normothermic Isolated Limb Infusion of Melphalan

NCT00421811

Phase 1/2 Completed 56 enrolled Adherex Technologies, Inc.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

N-cadherin, a protein involved in blood vessel cell binding and on the surface of many tumor cells, is increased as cancer progresses. ADH-1 blocks N-cadherin. This study will test the safety and effects of the combination ADH-1 with Normothermic Isolated Limb Infusion of Melphalan in subjects with locally advanced malignant melanoma.

Timeline

Start
2007-04
Primary completion
2009-03
Completion
2009-03

Drugs

EvaluationDrugModalityDoseRoute
Subject ADH-1 Protein / enzyme biologic 4 g Intravenous
Subject Melphalan Small molecule 0.0075 mg/ml Other
Subject Melphalan Small molecule 0.01 mg/ml Other

Indications